Forte Biosciences, Inc.

NASDAQ:FBRX

Biotechnology

Healthcare
$76.99 +1.71%

+$0.30 today

Market cap
$1.58B
Beta
2.87
P/E (TTM)
-42.1
EPS (TTM)
-$0.43
52W Low $9.10High $35.80

Volume 0.00M

Average 0.30M

FBRX Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Forte Biosciences, Inc.NASDAQ: FBRX

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI turns negative

Q1 FY2026 Accumulated OCI was -$4K, compared with $0 a year earlier.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 2 of the last 3 fiscal years.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4K-233.3% QoQ
Last fiscal yearDec 2025
$3K-72.7% YoY
Year agoMar 2025
$0— since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-72.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
3K USD
Year-over-year change
-72.7%

Accumulated OCI vs competitors

How FBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
  • Accumulated OCI amounts to 0.0% of total assets for FBRX, versus a peer median of 0.0%.
FBRX Competitors
Accumulated OCI for FBRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MOLNMolecular Partners AGMar 2026CHF 0 CHF——0.0%
ACTUActuate Therapeutics IncMar 2026$0 USD——0.0%
FBRXForte Biosciences, Inc.Mar 2026-$4K USD——0.0%
CRDFCardiff Oncology, Inc.Mar 2026-$49K USD-281.5%—0.1%
PEPGPepGen Inc.Mar 2026-$59K USD-168.2%—0.0%
FATEFate Therapeutics, Inc.Mar 2026-$77K USD-140.3%—0.0%
ALECAlector, Inc.Mar 2026-$104K USD-154.5%—0.0%
ELTXElicio Therapeutics, Inc.Mar 2026-$122K USD+15.3%—0.5%
NKTXNkarta, Inc.Mar 2026-$130K USD-119.9%—0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026-$161K USD-600.0%—0.1%
Peer median (excluding FBRX) —-154.5%—0.0%

Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents42.04M41.1M11.96M22.24M76.96M
Short-term Investments0025.16M36.12M0
Net Receivables0000817K
Inventory00000
Other Current Assets89K70K165K336K422K
Total Current Assets42.52M41.51M38.33M61.35M80.59M
Property, Plant & Equipment (Net)00109K77K129K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets786K486K544K138K2.06M
Total Non-current Assets786K486K653K215K2.19M
Total Assets43.31M42M38.98M61.56M82.78M
Account Payables946K1.15M1.42M4.88M9.99M
Short-term Debt00000
Tax Payables00001.04M
Deferred Revenue00000
Other Current Liabilities681K890K947K1.55M2.25M
Total Current Liabilities1.76M3.18M3.67M9.08M20.75M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00001.04M
Total Non-current Liabilities00001.04M
Total Liabilities1.76M3.18M3.67M9.08M21.79M
Common Stock15K21K36K6K13K
Retained Earnings(73.17M)(87.04M)(118.52M)(154M)(223.37M)
Accumulated OCI(43.31M)04K11K3K
Other Stockholders Equity00000
Minority Interest00000
Total Equity41.55M38.82M35.31M52.48M60.99M
Total Debt00000
Net Debt(42.04M)(41.1M)(11.96M)(22.24M)(76.96M)

Forte Biosciences, Inc.

NASDAQ:FBRX

Intrinsic Alpha fair value

Locked

Current Price

$76.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.